Plakophilin-2 (PKP2) gene therapy using AAV vector
US11883506B2 · kind B2 · utility
0Cited by
26References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 11, 2022 |
| Grant date | Jan 30, 2024 |
| Priority date | — |
| Expiry date | Feb 11, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein is a gene therapy for PKP2 (Plakophilin-2), e.g. using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter or a cardiac troponin T (HTNNT2) promoter. The capsid may be an AAV9 or AAVrh74 capsid or a functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the rAAV vector, and other compositions and methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.